This is a companion infographic to our main story about Eli Lilly & Co.’s withdrawal of its soft tissue sarcoma treatment Lartruvo (olaratumab) from markets worldwide. The information is based on US Food and Drug Administration data compiled by the Pink Sheet.
Accelerated Approval Withdrawals Through The Years
Lartruvo’s brief time on the market is especially quick compared with other drugs and indications that received accelerated approval from the US FDA and were subsequently withdrawn, our infographic shows.
More from Approval Standards
More from Pathways & Standards
• By
Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.
• By
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
• By
Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.